Schedules of Controlled Substances: Placement of Embutramide Into Schedule III; Extension of Comment Period, 50996 [05-17163]

Download as PDF 50996 Proposed Rules Federal Register Vol. 70, No. 166 Monday, August 29, 2005 This section of the FEDERAL REGISTER contains notices to the public of the proposed issuance of rules and regulations. The purpose of these notices is to give interested persons an opportunity to participate in the rule making prior to the adoption of the final rules. FOR FURTHER INFORMATION CONTACT: DEPARTMENT OF JUSTICE Christine A. Sannerud, Ph.D., Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307–7183. Drug Enforcement Administration 21 CFR Part 1308 [Docket No. DEA–269N] Schedules of Controlled Substances: Placement of Embutramide Into Schedule III; Extension of Comment Period Drug Enforcement Administration (DEA), Department of Justice. ACTION: Notice of proposed rulemaking; extension of comment period. AGENCY: SUMMARY: The Drug Enforcement Administration (DEA) is extending the comment period and time to request a hearing on the Federal Register Notice of proposed rulemaking entitled ‘‘Schedules of Controlled Substances: Placement of Embutramide into Schedule III’’ published on July 29, 2005 (70 FR 43809). DATES: The period for public comment that was to close on August 29, 2005, will be extended to September 28, 2005. ADDRESSES: To ensure proper handling of comments, please reference ‘‘Docket No. DEA–269P’’ on all written and electronic correspondence. Written comments being sent via regular mail should be sent to the Deputy Administrator, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL. Written comments sent via express mail should be sent to the Deputy Administrator, Drug Enforcement Administration, Attention: DEA Federal Register Representative/ ODL, 2401 Jefferson Davis Highway, Alexandria, VA 22301. Comments may be directly sent to DEA electronically by sending an electronic message to dea.diversion.policy@usdoj.gov. Comments may also be sent electronically through https:// www.regulations.gov using the electronic comment form provided on that site. An electronic copy of this VerDate Aug<18>2005 13:16 Aug 26, 2005 document is also available at the https:// www.regulations.gov Web site. DEA will accept electronic comments containing MS Word, WordPerfect, Adobe PDF, or Excel file formats only. DEA will not accept any file format other than those specifically listed here. Jkt 205001 DEA published a Notice of Proposed Rulemaking (70 FR 43809) proposing the placement of embutramide into Schedule III of the Controlled Substances Act (CSA). The proposed scheduling action is based on a scientific and medical evaluation and recommendation by the Department of Health and Human Services and an evaluation of this and other information by DEA. On August 22, 2005, DEA received a request for an extension of the period in which to comment and request a hearing. The requestor indicated that the additional time is necessary to review the scientific articles and other information cited by DEA in support of its scheduling proposal. Upon consideration of this request, a thirty day extension of the time to comment and request a hearing is granted. This allows sufficient time for interested persons to evaluate and consider all relevant information and respond accordingly. Therefore, the comment period and time to request a hearing is extended to September 28, 2005. Comments must be received by the DEA on or before this date. SUPPLEMENTARY INFORMATION: Dated: August 24, 2005. Michele M. Leonhart, Deputy Administrator. [FR Doc. 05–17163 Filed 8–26–05; 8:45 am] BILLING CODE 4410–09–P PO 00000 Frm 00001 Fmt 4702 Sfmt 4702 DEPARTMENT OF LABOR Occupational Safety and Health Administration 29 CFR Part 1926 [Docket No. H023] RIN 1218–AC18 Notice of a Regulatory Flexibility Act Review of Lead in Construction Occupational Safety and Health Administration, Labor. ACTION: Extension of comment period. AGENCY: SUMMARY: The Occupational Safety and Health Administration (OSHA) is conducting a review of the lead in construction standard, 29 CFR 1926.62, under Section 610 of the Regulatory Flexibility Act and Section 5 of Executive Order 12866 on Regulatory Planning and Review. On June 6 (70 FR 32739–42), OSHA requested comments for that review, provided background and gave information on the issues. Requests have been received to extend the comment period to permit the public more time to gather and submit information. Accordingly, OSHA is extending the period. DATES: Written comments to OSHA must be sent or postmarked by November 7, 2005. ADDRESSES: You may submit three copies of your written comments to the OSHA Docket Office, Docket No. H023, Technical Data Center, Room N–2625, U.S. Department of Labor, 200 Constitution Avenue NW., Washington, DC 20210; telephone (202) 693–2350. If your written comments are 10 pages or fewer, you may fax them to the OSHA Docket Office at (202) 693–1648. You do not have to send OSHA a hard copy of your faxed comments. Supplemental information such as studies and journal articles cannot be attached. Instead, three copies of each study, article, or other supplemental document must be sent to the OSHA Docket Office at the address above. These materials must clearly identify the associated comments to which they will be attached in the docket by the following information: Name of person submitting comments; date of comment submission; subject of comments; and docket number to which comments belong. E:\FR\FM\29AUP1.SGM 29AUP1

Agencies

[Federal Register Volume 70, Number 166 (Monday, August 29, 2005)]
[Proposed Rules]
[Page 50996]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-17163]


========================================================================
Proposed Rules
                                                Federal Register
________________________________________________________________________

This section of the FEDERAL REGISTER contains notices to the public of 
the proposed issuance of rules and regulations. The purpose of these 
notices is to give interested persons an opportunity to participate in 
the rule making prior to the adoption of the final rules.

========================================================================


Federal Register / Vol. 70, No. 166 / Monday, August 29, 2005 / 
Proposed Rules

[[Page 50996]]



DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Part 1308

[Docket No. DEA-269N]


Schedules of Controlled Substances: Placement of Embutramide Into 
Schedule III; Extension of Comment Period

AGENCY: Drug Enforcement Administration (DEA), Department of Justice.

ACTION: Notice of proposed rulemaking; extension of comment period.

-----------------------------------------------------------------------

SUMMARY: The Drug Enforcement Administration (DEA) is extending the 
comment period and time to request a hearing on the Federal Register 
Notice of proposed rulemaking entitled ``Schedules of Controlled 
Substances: Placement of Embutramide into Schedule III'' published on 
July 29, 2005 (70 FR 43809).

DATES: The period for public comment that was to close on August 29, 
2005, will be extended to September 28, 2005.

ADDRESSES: To ensure proper handling of comments, please reference 
``Docket No. DEA-269P'' on all written and electronic correspondence. 
Written comments being sent via regular mail should be sent to the 
Deputy Administrator, Drug Enforcement Administration, Washington, DC 
20537, Attention: DEA Federal Register Representative/ODL. Written 
comments sent via express mail should be sent to the Deputy 
Administrator, Drug Enforcement Administration, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson Davis Highway, Alexandria, 
VA 22301. Comments may be directly sent to DEA electronically by 
sending an electronic message to dea.diversion.policy@usdoj.gov. 
Comments may also be sent electronically through https://
www.regulations.gov using the electronic comment form provided on that 
site. An electronic copy of this document is also available at the 
https://www.regulations.gov Web site. DEA will accept electronic 
comments containing MS Word, WordPerfect, Adobe PDF, or Excel file 
formats only. DEA will not accept any file format other than those 
specifically listed here.

FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief, 
Drug and Chemical Evaluation Section, Drug Enforcement Administration, 
Washington, DC 20537, Telephone: (202) 307-7183.

SUPPLEMENTARY INFORMATION: DEA published a Notice of Proposed 
Rulemaking (70 FR 43809) proposing the placement of embutramide into 
Schedule III of the Controlled Substances Act (CSA). The proposed 
scheduling action is based on a scientific and medical evaluation and 
recommendation by the Department of Health and Human Services and an 
evaluation of this and other information by DEA. On August 22, 2005, 
DEA received a request for an extension of the period in which to 
comment and request a hearing. The requestor indicated that the 
additional time is necessary to review the scientific articles and 
other information cited by DEA in support of its scheduling proposal. 
Upon consideration of this request, a thirty day extension of the time 
to comment and request a hearing is granted. This allows sufficient 
time for interested persons to evaluate and consider all relevant 
information and respond accordingly. Therefore, the comment period and 
time to request a hearing is extended to September 28, 2005. Comments 
must be received by the DEA on or before this date.

    Dated: August 24, 2005.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. 05-17163 Filed 8-26-05; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.